Constance Guille, M.D., a reproductive psychiatrist and the director of the MUSC Women’s Reproductive Behavioral Health Program, details the first FDA-approved treatment for moderate to severe postpartum depression. This treatment, a brexanolone (Zulresso) infusion, provides symptom relief within days instead of the weeks or months required with traditional antidepressants. Guille also discusses the far-reaching impacts of mood and anxiety disorders on pregnant and postpartum women as well as their children.
Related Presenters
Rank Associate Professor College College of Medicine Department Psychiatry and Behavioral Sciences Academic Focus Women's Health Perinatal Psychiatry Stress and Depression
Related Videos
